Skip to content
IGI grad logo
  • About Us
    • Our Approach NewGreenArrow
      Centers of Innovation NewGreenArrow
      Management Team NewGreenArrow
      Board of Directors NewGreenArrow
      Scientific Advisory Board NewGreenArrow
      Our Approach NewGreenArrow
      Centers of Innovation NewGreenArrow
      Our Team NewGreenArrow
      Leadership
      Governance Board
      Scientific Advisory Board
  • Corporate Presentation
  • Pipeline
  • Partnerships
  • News Center
    • News & Media NewGreenArrow
      Publications NewGreenArrow
  • Careers
    • Our Culture NewGreenArrow
      Join Us NewGreenArrow
  • Home
  • About Us
    • Our Approach
    • Centers of Innovation
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Corporate Presentation
  • Pipeline
  • Partnerships
    • Partnerships
  • News Center
    • News & Media
    • Publications
  • Careers
    • Our Culture
    • Join Us
  • Contact Us
  • Home
  • About Us
    • Our Approach
    • Centers of Innovation
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Corporate Presentation
  • Pipeline
  • Partnerships
    • Partnerships
  • News Center
    • News & Media
    • Publications
  • Careers
    • Our Culture
    • Join Us
  • Contact Us

corporate

  1. Home>
  2. corporate

Corporate update – August 2024 Update

  • Post published:August 13, 2024
  • Post category:corporate

DATE: 13 August 2024 CATEGORY: CORPORATE UPDATE August 2024 Update About IGIIchnos Glenmark Innovation (IGI) is an alliance between Ichnos Sciences Inc., a global fully integrated clinical-stage biotech company developing multispecifics™…

Continue ReadingCorporate update – August 2024 Update

Recent Updates

  • Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma
    May 3, 2025/
    0 Comments
  • Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple Myeloma​
    December 9, 2024/
    0 Comments
  • Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting
    November 4, 2024/
    0 Comments
  • IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer
    September 30, 2024/
    0 Comments
  • IGI Announces Publication in Nature Cancer on ISB 2001, IGI’s Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma
    September 11, 2024/
    0 Comments

We are open for collaboration

Contact Us
For the latest updates, follow us on
  • Linkedin

Want to create something cutting edge with us? Join us.

We are open for collaboration

For the latest updates, follow us on
  • Linkedin

Want to create something cutting edge with us? Join us.

Contact Us
igi_logo_bott_a
Ichnos Glenmark Innovation creates cutting-edge solutions to treat haematological malignancies and solid tumours to bring new hope for patients and healthcare professionals alike.
  • Terms of Use
  • Privacy Policy
  • Cookies Policy

Get in Touch

© Copyright 2025. All Rights Reserved by IGI.

© Copyright 2025. All Rights Reserved by IGI.

  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Contact Us
  • Linkedin